Empagliflozin reduces albuminuria: a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial
Publikation: Bidrag til tidsskrift › Leder › Forskning
Standard
Empagliflozin reduces albuminuria : a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial. / Borg, Rikke; Persson, Frederik.
I: Journal of Translational Medicine, Bind 5, Nr. 23, 478, 2017.Publikation: Bidrag til tidsskrift › Leder › Forskning
Harvard
Borg, R & Persson, F 2017, 'Empagliflozin reduces albuminuria: a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial', Journal of Translational Medicine, bind 5, nr. 23, 478. https://doi.org/10.21037/atm.2017.11.02
APA
Borg, R., & Persson, F. (2017). Empagliflozin reduces albuminuria: a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial. Journal of Translational Medicine, 5(23), [478]. https://doi.org/10.21037/atm.2017.11.02
Vancouver
Borg R, Persson F. Empagliflozin reduces albuminuria: a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial. Journal of Translational Medicine. 2017;5(23). 478. https://doi.org/10.21037/atm.2017.11.02
Author
Bibtex
@article{82e2e6a7c7fb47ef80f63ba66f30fb0c,
title = "Empagliflozin reduces albuminuria: a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial",
author = "Rikke Borg and Frederik Persson",
year = "2017",
doi = "10.21037/atm.2017.11.02",
language = "English",
volume = "5",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "23",
}
RIS
TY - JOUR
T1 - Empagliflozin reduces albuminuria
T2 - a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial
AU - Borg, Rikke
AU - Persson, Frederik
PY - 2017
Y1 - 2017
U2 - 10.21037/atm.2017.11.02
DO - 10.21037/atm.2017.11.02
M3 - Editorial
C2 - 29285511
VL - 5
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
SN - 1479-5876
IS - 23
M1 - 478
ER -
ID: 188530464